Search
Close this search box.

Philips and SyntheticMR launch AI-based quantitative brain imaging system     

In the rapidly evolving field of medical diagnostics, Philips and Synthetic MR have embarked on a collaboration to enhance the diagnosis of neurological disorders using advanced quantitative brain imaging tools.

This partnership aims to revolutionise the detection and analysis of conditions such as multiple sclerosis, traumatic brain injuries, and dementia.

Typically diagnosed through a blend of medical history assessment, physical examination, and diagnostic tests, these disorders now stand on the cusp of a new era with the introduction of the Smart Quant Neuro 3D MRI machine software suite.

This innovative software suite leverages a combination of three previously released technologies: Philips’ SmartSpeed image-reconstruction technology, the 3D SyntAc clinical application, and SyntheticMR’s SyMRI NEURO 3D quantitative tissue assessment software.

Together, they employ AI to analyse brain tissues, including white matter, grey matter, cerebrospinal fluid, and myelin, marking an advancement in the diagnosis of traumatic brain injuries beyond traditional symptom-based tests.

According to GlobalData, a leading data and analytics company, AI in the diagnostic imaging market is projected to reach $1.2bn by 2027, signifying a transformative shift towards enhancing accuracy, efficiency, and patient outcomes in medical imaging.

Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free
sample

Your download email will arrive shortly

We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form

By GlobalData

The diagnostic imaging market, particularly magnetic resonance imaging systems, which was valued at $6.2bn in 2023, is expected to grow to $9.1bn by 2030.

This growth is fueled by the demand for early disease diagnosis and personalised medicine, driving advancements in software, hardware, and consumables within the sector.

AI’s potential to improve image analysis efficiency and precision is a testament to its rapid evolution across various medical domains.

By integrating AI systems and computer vision, the technology assists radiologists and healthcare professionals in identifying abnormalities in tissues in scan images, thereby streamlining workloads and suggesting potential treatment pathways based on patients’ medical histories.

Further development in AI could also bolster molecular imaging research, essential for understanding diseases at the cellular level.

Philips and Synthetic MR’s collaboration represents a pivotal moment in diagnostic imaging, contributing to the sector’s increasingly crucial role in preventive healthcare and early disease detection.

As the global population ages and the prevalence of diseases such as cancer rises, the efficiency, accuracy, and accessibility of diagnoses are paramount.

This partnership not only showcases the potential of AI in medical imaging but also sets the stage for a new era of diagnostic capabilities that promise to significantly impact patient care and outcomes.